Weekly Digest – August 2026 Weekly Digest – August 2026 26 August 2026: Datroway phase 3 TROPION-Urothelial04 trial initiated as adjuvant therapy for high-risk MIUC Daiichi Sankyo and AstraZeneca announced the initiation of the phase 3 TROPION-Urothelial04 trial, with the […]
Weekly Digest – August 2026 Weekly Digest – August 2026 26 August 2026: CSPC announced that SYS6010 met the pre-specified primary endpoint in phase 3 trial CSPC Pharmaceutical Group announced that its EGFR-targeted ADC SYS6010 met the pre-specified primary endpoint […]
Weekly Digest – August 2026 Weekly Digest – August 2026 17 August 2026: Enhertu significantly improved PFS as 1L treatment in HER2-mutant advanced NSCLC in the phase 3 DESTINY-Lung04 trial AstraZeneca and Daiichi Sankyo announced that Enhertu demonstrated a statistically […]
Weekly Digest – August 2026 Weekly Digest – August 2026 18 August 2026: Iza-bren phase 3 trial met its primary endpoint in locally advanced/metastatic NSCLC Biokin announced that the phase 3 BL-B01D1-301 trial of Iza-bren met its pre-specified primary endpoint of […]
Weekly Digest – July 2026 Weekly Digest – July 2026 21 July 2026: Telix doses first patient in phase 3 LUTEON trial of TLX250-Tx for Renal cancer Telix Pharmaceuticals announced the first patient dosing in the pivotal phase 3 LUTEON […]
Weekly Digest – July 2026 Weekly Digest – July 2026 10 July 2026: Hansoh Pharma announces ARTEMIS-008 trial achieved primary OS endpoint in SCLC Hansoh Pharma announced that its B7-H3-targeted antibody-drug conjugate Risvutatug rezetecan met the primary endpoint of overall […]
Weekly Digest – July 2026 Weekly Digest – July 2026 15 July 2026: Kelun-Biotech’s phase 3 trial of Sac-TMT plus Pembrolizumab met the primary endpoint in 1L PD-L1-negative non-squamous NSCLC Kelun-Biotech announced that its TROP2-targeted antibody-drug conjugate Sacituzumab tirumotecan, in […]
Weekly Digest – July 2026 Weekly Digest – July 2026 30 June 2026: CSPC initiates phase 3 trial of SYS-6010 in combination with Enlonstobart in resected stage II–IIIB NSCLC CSPC Pharmaceutical Group has initiated the phase 3 SYS6010-015 trial in […]
Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first patient Akeso has announced the enrollment of the first patient in the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Merck and Gilead discontinue phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus Keytruda in 1L metastatic NSCLC Merck and Gilead have announced the discontinuation of the phase 3 […]
